Gastroesophageal refl ux disease and cardiovascular disease: comorbidity features.
https://doi.org/10.31146/1682-8658-ecg-200-4-33-40
Abstract
Study of comorbidity features of gastroesophageal refl ux disease (GERD) and cardiovascular diseases (CVD) due to their frequent occurrence and mutual infl uence is still urgent, which was the aim of our study. Overall 357 people (men — 26,9%; women — 73,1%) were interviewed. GERD was registered in 8.7% of cases (men — 13.5%; women — 6.5%). Its detection rate naturally increased with increasing age, as well as obesity, hypertension, coronary heart disease, heart rhythm disorders and chronic heart failure. GERD was signifi cantly more common in GERD than in the absence of GERD. Common risk factors (obesity, tobacco smoking and alcohol abuse) were signifi cantly more frequent in GERD and CVD compared to the absence of GERD. The highest comorbidity of GERD and CVD was found in patients with GERD under 5 years compared to those with a history of GERD of 5 years or more. This is associated with the fact that in the absence of GERD the incidence of CVD increased with increasing age and did not with GERD. The latter is explained by the fact that the registration of such common FRS of GERD and CVD, as obesity, tobacco smoking and alcohol abuse in the absence of GERD naturally increased with increasing age, while this did not occur in the presence of GERD. Close associative link between GERD and CVD was established. It was determined both by risk factors common for them (obesity, tobacco smoking and alcohol abuse) and by age of patients and duration of GERD.
About the Authors
N. P. Kirilenko
Tver State Medical University
Russian Federation
Russian Federation
Nikolai P. Kirilenko, Doctor of Medical Sciences, Associate Professor, Professor of the Department of Polyclinic Therapy and Family Medicine
Scopus Author ID: 7003736426
4, Sovetskaya St., Tver, 170100
N. N. Ilyina
Tver State Medical University
Russian Federation
Russian Federation
Natalya N. Ilyina, Ph. D. Sci., Assistant Professor, Department of Management and Economics of Pharmacy with Courses in Pharmacognosy, Pharmaceutical Technology, Pharmaceutical and Toxicological Chemistry
4, Sovetskaya St., Tver, 170100
References
1. Oganov R. G., Denisov I. N., Simanenkov V. I., et al. Comorbid Pathology in Clinical Practice. Clinical guidelines. Cardiovascular Therapy and Prevention. 2017;16(6):5–56. (in Russ.) doi: 10.15829/1728–8800–2017–6–5–56
2. Lazebnik L.B., Konev Y. V. Historical features and semantic diffi culties of the use of terms denoting the multiplicity of diseases in one patient. Experimental and Clinical Gastroenterology. 2018;154(6):4–9. (in Russ.)
3. Simonova J.G., Prikhodko M. N., Shulgina E. M., Filatov M. A. Monitoring of clinical and endoscopic picture in patients with stable angina associated with gastroesophageal reflux disease. Experimental and Clinical Gastroenterology. 2019;(6):9–14. (in Russ.) doi: 10.31146/1682–8658-ecg-166–6–9–14
4. Larina V.N., Bondarenkova A. A., Lunev V. I., Golovko M. G. Extraesophageal symptoms of gastroesophageal reflux disease as manifestations of polymorbidity. Experimental and clinical gastroenterology. 2019;(6):4–8. (in Russ.) doi: 10.31146/1682–8658-ecg-166–6–4–8
5. Kuipers E. J., Spaander M. C. Natural History of Barrett’s Esophagus. Dig Dis Sci. 2018;63(8):1997–2004. doi: 10.1007/s10620–018–5161
6. Eusebi L. H., Ratnakumaran R., Yuan Y., et аl. Global prevalence of, and risk factors for, gastro- oesophageal refl ux symptoms: a meta-analysis. Gut. 2018;67(3):430‐440. doi: 10.1136/gutjnl-2016–313589
7. Lazebnik L.B., Masharova A. A., Bordin D. Results of a multicenter study “Epidemiology of gastroesophageal refl ux disease in Russia (MEGRE)”. Ter. Archiv. 2011;1;45–50. (in Russ.)
8. Pogosova N.V., Oganov R. G., Boitsov S. A., et al. Analysis of key indicators of secondary prevention in patients with coronary heart disease in Russia and Europe according to the results of Russian part of international multicenter study EUROASPIRE V. Cardiovascular Th erapy and Prevention. 2020;19(6):2739. (in Russ.) doi: 10.15829/1728–8800–2020–2739
9. Lei W-Y., Wang J-H., Wen S-H., et al. Risk of acute myocardial infarction in patients with gastroesophageal refl ux disease: A nationwide population- based study. PLoS One. 2017;12(3): e0173899.
10. Chen C.H., Lin C. L., Kao C. H. Association between gastroesophageal refl ux disease and coronary heart disease: A nationwide population- based analysis. Medicine. 2016;95(27): e4089.
11. Alekseeva O.P., Pikulev D. V. Gastroesophageal refl ux disease and ischemic heart disease – is there a syndrome of mutual aggravation? Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(4):66–73. (in Russ.) doi: 10.22416/1382–4376–2019–29–4–66–73
12. Locke G.R., Talley N. J., Weaver A. L., Zinsmeister A. R. A new questionnaire for gastroesophageal refl ux disease. Mayo Clin Proc. 1994;69:539–47. doi: 10.1016/s0025–6196(12)62245–9
13. Starostin B. D. Gastroesophageal refl ux disease (part I). Epidemiology, risk factors. Gastroenterology of St. Petersburg. 2014; 1; 2–14. (in Russ.)
14. Christopher Harrison, Joan Henderson, Graeme Miller, Helena Britt. Th e prevalence of diagnosed chronic conditions and multimorbidity in Australia: A method for estimating population prevalence from general practice patient encounter data. PLOS ONE. doi: 10.1371/journal.pone.0172935
15. Balanova A.Y, Shalnova S. A., Deev A. D., et al. Obesity in the Russian population – prevalence and associations with risk factors of chronic noninfectious diseases. Russian Journal of Cardiology. 2018;(6):123–30. (in Russ.) doi: 10.15829/1560–4071–2018–6–123–130
16. Gambaryan M.G., Drapkina O. M. Prevalence of Tobacco Consumption in Russia: Dynamics and Trends. Analysis of the results of global and national surveys. Preventive Medicine. 2018;21(5):45–62. doi: 10.17116/profmed20182105145
17. Kirilenko N.P., Koroleva O. M., Krasnenkov V. L., Solovyova A. V., Zhmakin I. A., Kalinkin M. N. Mobile health care in the Tver region: from idea to implementation and promotion. Preventive Medicine. 2019;22(3):44–50. (in Russ.) doi: org/10.17116/profmed20192203144
18. Shalnova S.A., Maksimov S. A., Balanova Yu.A., et al. (on behalf of ESSE-RF researchers). Alcohol consumption and dependence on socio- demographic factors in persons of working age (according to the ESSE-RF study). Preventive Medicine. 2019;22(5):45–53. doi: 10.17116/profmed20192205145
19. Boytsov S.A., Drapkina O. M., Shlyakhto E. V., et al. ESSE-RF study (Epidemiology of cardiovascular diseases and their risk factors in regions of the Russian Federation). Ten years later. Cardiovascular Th erapy and Prevention. 2021;20(5):3007. (in Russ.) doi: 10.15829/1728–8800–2021–3007
20. Kontsevaya A.V., Drapkina O. M. Economics of prevention of noninfectious diseases. Preventive Medicine. 2018;21(2): 4–10. doi: 10.17116/profmed20182124–10
21. Boeckxstaens G., El- Serag H.B., Smout A. J., Kahrilas P. J. Symptomatic refl ux disease: the present, the past and the future. Gut. 2014;63(7):1185–1193. doi: 10.1136/gutjnl-2013–306393
22. Starostin B. D. Modern approaches to treatment of gastroesophageal ref lux disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(1):7–16. (in Russ.) doi: 10.22416/1382–4376–2019–29–1–7–16
23. Burmaleeva R.R., Chernova A. S. Adherence to a healthy lifestyle in diff erent age groups among the population of Saratov. Bulletin of Medical Internet Conferences (ISSN 2224–6150) 2020. Volume 10. Issue 9. ID: 2020–09–8-A-19297 (in Russ.)
Review
For citations:
Kirilenko N.P., Ilyina N.N. Gastroesophageal refl ux disease and cardiovascular disease: comorbidity features. Experimental and Clinical Gastroenterology. 2022;(4):33-40. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-200-4-33-40
Views:
449
Email this article 